title: Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models.
abstract: The nephrotoxic potential of ascomycin, the C21-ethyl analogue of FK506, was defined and ways explored to enhance its detection. After 14-day dosing in the Fischer-344 rat, FK506 and ascomycin reduced creatinine clearance by >50% at doses of 1 and 3 mg/kg, i.p., respectively. Ascomycin also had a 3-fold lower immunosuppressive potency in a popliteal lymph node hyperplasia assay, resulting in an equivalent therapeutic index consistent with a common mechanistic dependence on calcineurin inhibition. Renal impairment with different routes of administration was correlated with pharmacokinetics. Sensitivity of detection was not adequate with shorter dosing durations in rats with unilateral nephrectomy or in mice using a cytochrome P-450 inhibitor, SKF-525A. In 14-day studies, nephrotoxicity was not induced by continuous i.p. infusion of ascomycin at 10 mg/kg/day or daily oral administration (up to 50 mg/kg/day) in rats on a normal diet, nor by continuous i.v. infusion (up to 6 mg/kg/day) in rats on a low salt diet to enhance susceptibility. The lack of toxicity at high oral doses of FK506 or ascomycin, and the finding of non-linear oral pharmacokinetics of ascomycin show that this drug class has an oral absorption ceiling. The negative results with continuous infusion suggest that ascomycin nephrotoxicity is governed by peak drug levels. In addition to defining ways to meaningfully compare the nephrotoxic potential of FK506 derivatives, these results have implications for overall safety assessment and improved clinical use.
authors.affiliation: Immunologic Diseases Area, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
authors.forename: K W
authors.initials: KW
authors.lastname: Mollison
authors.forename: T A
authors.initials: TA
authors.lastname: Fey
authors.forename: R A
authors.initials: RA
authors.lastname: Krause
authors.forename: J M
authors.initials: JM
authors.lastname: Andrews
authors.forename: P T
authors.initials: PT
authors.lastname: Bretheim
authors.forename: P K
authors.initials: PK
authors.lastname: Cusick
authors.forename: G C
authors.initials: GC
authors.lastname: Hsieh
authors.forename: J R
authors.initials: JR
authors.lastname: Luly
mesh_terms: D000818:Animals; D001682:Biological Availability; D004039:Diet, Sodium-Restricted; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004353:Drug Evaluation, Preclinical; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D008815:Mice, Inbred Strains; D008954:Models, Biological; D009392:Nephrectomy; D051381:Rats; D011919:Rats, Inbred Strains; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity*
chemical_list: D007166:Immunosuppressive Agents; C058028:immunomycin; D016559:Tacrolimus